Scholars Central

PerspectivePublished 27 Oct 2023

Gastric Adenocarcinoma Management: A Perspective

Authors: Carlos A. Cardenas, Shabnam Abrishami

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Gastric Adeno Carcinoma (GAC) remains a formidable global health challenge, marked by its geographical variability and the pressing need for improved therapeutic strategies. This opinion piece aims to delve into recent strides made in GAC management, with a specific focus on the localized and metastatic settings. We explore the details of adjunctive therapy for localized GAC and discuss the promising developments, including immune checkpoint inhibitors, for Microsatellite Instability High (MSI-H) GAC. In the metastatic arena, we survey the evolving realm of targeted therapies and immune checkpoint inhibitors, highlighting the recent approval of trastuzumab deruxtecan for HER-2-positive GAC. We also contemplate the prospects of claudin 18.2 (CLDN18.2) and Fibroblast Growth Factor Receptor (FGFR) as novel therapeutic targets in GAC.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Oncology: Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Oncology: Case Reports
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Carlos A. Cardenas”
  • BylineArticles whose byline prints “Shabnam Abrishami”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels